TransCelerate Advances Digital Protocols in Clinical Trials
TransCelerate is advancing its Digital Data Flow (DDF) initiative to modernize clinical trials by embracing digital protocols, announced in a press release. The initiative aims to address the industry's reliance on unstructured documents, which currently account for 90% of clinical trial protocols, by promoting the adoption of structured, digital formats.
At recent events in the U.S. and Europe, TransCelerate highlighted the growing industry momentum towards digital protocols, with participation from sponsors, regulators, and solution providers. These events showcased the benefits of the Unified Study Definitions Model (USDM) version 4, which provides a standardized, machine-readable format for clinical trial protocols, facilitating automation and data reuse.
The adoption of digital protocols is expected to enhance regulatory compliance, improve efficiency, and foster innovation across the clinical trial ecosystem. TransCelerate's efforts align with global regulatory trends and are supported by its member companies, who collectively invest $125 billion annually in research and development.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Trend report
Cybersecurity Trends Report 2025
The Cybersecurity Trends Report 2025 by Netwrix Research Lab provides insights into how organizations are adapting their cybersecurity strategies amidst growing AI adoption. The report, based on a survey of 2,150 IT professionals from 121 countries, highlights key trends such as the increase in hybrid IT environments, AI-driven security challenges, and the rising costs of security incidents.
Read more